NASDAQ$ETNB

89Bio Inc · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

89bio reported Q1 2025 a net loss of $71.3M, diluted EPS of $(0.49).

For Q1 2025, 89bio reported net loss was $71.3M, diluted EPS was $-0.49. Management discusses operating trends, liquidity, and outlook in the quarterly filing.

  • Net loss $71.3M.
  • Diluted EPS $-0.49.
  • MD&A highlights operating priorities, liquidity, and sector-specific risks.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.49

Previous: -$0.54+9.3%
Research and Development Expenses

$64.4M

No prior period
General and Administrative Expenses

$11.5M

No prior period
Total Operating Expenses

$75.9M

No prior period
Interest Expense

-$1.27M

No prior period
Interest Income and Other, Net

$6.04M

No prior period
Net Loss Before Income Tax

-$71.1M

No prior period
Income Tax Expense

-$137K

No prior period
Comprehensive Loss

-$71.5M

No prior period
Net Loss Per Share, Basic and Diluted

-$0.49

No prior period
Weighted-Average Shares Used to Compute Net Loss Per Share, Basic and Diluted

146.4M

No prior period
Net Income

-$71.3M

Previous: -$51.7M-37.9%
Operating Income

-$75.9M

Previous: -$57.3M-32.5%

Revenue & EPS history

89Bio · Revenue · Quarterly

$0

Q1 2025
Beat estimate in 0 of 2 quarters(0%)
ActualEstimate

Forward guidance

Management emphasizes path to profitability, liquidity, and cost discipline.

Tailwinds

  • Operating initiatives and partnership milestones.
  • Cash runway and restructuring where applicable.

Headwinds

  • Operating losses and financing needs.
  • Macro and competitive uncertainty.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 7 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-0.1%

Avg return

Earnings day

-4.6%

Avg return

5 days after

-2.8%

Avg return

30 days after

54%

13 / 24 earnings

Positive

+14.8%

Q4 2019

Best reaction

-19.4%

Q1 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025+1.7%+1.3%-1.7%
Q1 2025-3.7%-4.1%+18.6%
Q4 2024-1.0%-7.1%-3.7%
Q3 2024+2.8%-10.9%-20.6%
Q2 2024-10.9%-11.8%-0.9%
Q1 2024-3.5%+0.8%-10.2%
Q4 2023+7.3%-0.2%-1.3%
Q3 2023-11.8%
Q2 2023+5.3%
Q1 2023+1.3%
Q4 2022-1.1%
Q3 2022+14.2%
Q2 2022+3.6%
Q1 2022+14.6%
Q4 2021+5.1%
Q3 2021+1.4%
Q2 2021+1.1%
Q1 2021-19.4%
Q4 2020-4.7%
Q3 2020-0.8%
Q2 2020+1.6%
Q1 2020-6.2%
Q4 2019+14.8%
Q3 2019-13.5%
Q2 2019
Q1 2019
Q4 2018
Q3 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro